EASi-KIDNEY video transcript
Dr Parminder Judge, Co-Principal Investigator, EASi-KIDNEY summarises what the trial's objective is
Introduction 00:00:00 --> 00:00:12
EASi-KIDNEYTM will be one of the largest trials ever conducted in patients with chronic kidney disease.
Main objective 00:00:12 --> 00:00:24
The trial's main objective is to test a new drug called BI 695107 in 11,000 people with kidney disease to see whether it can safely reduce the risk of the need for dialysis, dying from heart disease or preventing hospitalisation for heart failure.
Design 00:00:24 --> 00:00:48
The trial was designed and is being conducted by the Reno studies group in Oxford with a collaboration of international experts from about 15 to 20 countries. The trial's design is streamlined which means we focus on the main trial questions this will minimise the burden on participants and help integrate the trial into day-to-day clinical practice.
Conclusion 00:00:48 --> 00:00:59
We hope the trial will generate evidence which will positively impact patients with chronic kidney disease.